-
Deferasirox Fe3+ Chelate Research Workflows
2026-09-07
Build reproducible iron-speciation, uptake, and toxicity assays around a defined ferric chelate rather than treating it as interchangeable with free deferasirox. This guide combines practical DMSO handling, controls, comparative assay design, and clinically grounded interpretation for iron overload treatment research.
-
L-Alanyl-L-Glutamine: Practical GI Assay Guide
2026-09-05
L-Alanyl-L-Glutamine provides a defined, water-soluble dipeptide format for glutamine delivery in aqueous gastrointestinal, nutritional, and barrier-assay workflows. It is suitable for controlled aqueous studies but not for DMSO- or ethanol-based formulations or long-term storage of prepared solutions.
-
PRMT5, Splicing, and Metabolism in MYCN Neuroblastoma
2026-09-04
This Cancer Letters study shows that MYCN-amplified neuroblastoma depends on PRMT5-mediated control of RNA splicing, epitranscriptomic regulation, and glutamine metabolism. Its integrated transcriptomic, metabolic, molecular, and in vivo analyses identify GLS regulation as a mechanistic consequence of spliceosomal stress rather than an isolated metabolic phenotype.
-
Vasopressin Analogues: Innovation and Evidence
2026-09-04
Glavaš and colleagues review how vasopressin structure, receptor pharmacology, and peptide engineering have produced analogues with more selective antidiuretic, vasoconstrictive, or longer-acting profiles. The article is especially useful for interpreting lypressin, desmopressin, and terlipressin as distinct pharmacological tools while identifying the translational limits of peptide delivery and emerging antiviral hypotheses.
-
7-Ethyl-10-hydroxycamptothecin Research Workflows
2026-09-03
Build more informative cancer assays with 7-Ethyl-10-hydroxycamptothecin (SN-38), combining topoisomerase I stress, apoptosis, cell-cycle profiling, and FUBP1/FUSE readouts. This practical guide covers solvent handling, time-course design, metastatic colon cancer models, and troubleshooting for advanced oncology research.
-
Oltipraz: A Redox Lens on MASLD Assays
2026-09-03
Oltipraz offers a defined small-molecule framework for studying Nrf2-linked detoxification, oxidative stress, autophagy, and ferroptosis in MASLD research. This assay-centered guide explains how to connect phase II enzyme induction with the mechanistic findings of a recent QSHXO study without overstating translational evidence.
-
CB-839: A Mechanistic Probe of GLS1 Dependence
2026-09-02
CB-839 (Telaglenastat) provides a direct, reversible way to test GLS1 dependence in cancer metabolism research. This article connects PRMT5-linked glutamine disruption in MYCN-amplified neuroblastoma with practical assay decisions without conflating upstream splicing effects with direct glutaminolysis inhibition.
-
Cy3-UTP Workflow for RNA Nanoparticle Tracking
2026-09-02
Cy3-UTP enables direct, bright RNA labeling for in vitro transcription, particle tracking, RNA-protein interaction studies, and quantitative detection. This workflow translates nanoparticle structure-function findings into practical fluorescence controls while addressing labeling density, photostability, storage, and assay interpretation.
-
CB-839 (Telaglenastat) for Glutamine Metabolism
2026-09-01
CB-839 (Telaglenastat) provides a selective, reversible way to test whether GLS1-dependent glutaminolysis supports tumor growth, apoptosis, or autophagy. This workflow-focused guide connects metabolic assays with the PRMT5–splicing findings in MYCN-amplified neuroblastoma while preserving the distinction between published evidence and practical assay recommendations.
-
Tamoxifen in MCF-7 Assay Interpretation
2026-09-01
Tamoxifen is more than a selective estrogen receptor modulator in MCF-7 experiments. This guide explains how to interpret its effects on viability, migration, colony formation, and caveolin-1 while designing stronger mechanistic controls.
-
CB-839 (Telaglenastat) in Cancer Metabolism
2026-08-31
Build a robust CB-839 workflow that connects GLS1 inhibition with glutamine tracing, apoptosis, and autophagy measurements. The approach extends recent MYCN-neuroblastoma findings into practical cancer metabolism research and preclinical drug evaluation without treating upstream PRMT5 biology as a substitute for direct GLS1 inhibition.
-
Bradykinin (BA5201): Practical Workflow Guide
2026-08-31
This guide explains how to handle Bradykinin (BA5201) for controlled studies of vascular reactivity, permeability, smooth muscle responses, pain mechanisms, and inflammation signaling. It covers product-specific storage and handling requirements while distinguishing them from workflow recommendations; it is not a clinical, diagnostic, or medical-use protocol.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-08-30
The reference study shows that puerarin enhances osteogenic differentiation of rat dental follicle cells and links this response to nitric oxide–cGMP signaling. Its inhibitor-based design provides a useful framework for testing pathway involvement in periodontal regeneration research while highlighting the limits of cell-culture evidence.
-
4-Phenylbutyric Acid: A Causal ER Stress Tool
2026-08-29
Explore how 4-Phenylbutyric acid and 4-PBA can distinguish endoplasmic reticulum stress from downstream ferroptosis, apoptosis, and autophagy. This article presents a causal assay framework grounded in a PFOS-exposed kidney-cell study and practical reagent considerations.
-
CB-839 (Telaglenastat): Reliable Assays
2026-08-28
Learn how CB-839 (Telaglenastat), SKU B4799, can improve the design and interpretation of glutaminolysis inhibition assays in cancer metabolism research. This scenario-based guide connects GLS1 biology, practical compound handling, viability readouts, and splicing-linked metabolic vulnerability.